# A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Source: https://onco.cc/trials/nct04971226/  
OnCo record `nct04971226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Imatinib, Nilotinib, Bosutinib, Dasatinib and Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP is a phase 3 interventional study registered as NCT04971226 by Novartis Pharmaceuticals, with 405 participants enrolled, started 2021-10-06 and due to reach its primary completion in 2023-11-28. Interventions recorded: Imatinib, Nilotinib, Bosutinib, Dasatinib and Asciminib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04971226
- Phase: 3
- Setting: A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 405

## Sources

- ClinicalTrials.gov NCT04971226: https://clinicaltrials.gov/study/NCT04971226

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/), [Bosutinib](https://onco.cc/drugs/bosutinib/), [Dasatinib](https://onco.cc/drugs/dasatinib/), [Imatinib](https://onco.cc/drugs/imatinib/), [Nilotinib](https://onco.cc/drugs/nilotinib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct04971226.json